Orchid Pharma Limited — Q1 FY26 earnings call

Call held 12 Aug 2025

Management summary

Orchid Pharma reported a challenging Q1 FY26 with a significant 29% YoY decline in sales to INR 173 crores, primarily due to an unprecedented global slowdown in the antibiotics market. Despite this, the company maintained gross margins at 42% and achieved an operational EBITDA of INR 14 crores. A key strategic development was the acquisition of global rights to Enmetazobactam and the Exblifep trademark from Allecra, positioning Orchid as an innovator of an internationally approved new chemical entity. The company is also progressing with its 7ACA project and expects the Dhanuka Labs merger to complete within 6 months.

Highlights

  • Q1 FY26 sales stood at INR 173 crores, a steep decline of approximately 29% compared to INR 244 crores in the same period last year.

  • Gross margins were maintained at around 42% despite market pressures, achieved through disciplined pricing and product mix optimization.

  • Operational EBITDA for Q1 FY26 was INR 14 crores.

  • Orchid Pharma acquired global rights to Enmetazobactam and the trademark Exblifep from Allecra, gaining complete control over its regulatory and commercial strategy worldwide.

  • The 7ACA project in Jammu is progressing in line with revised timelines, with construction ongoing and major engineering equipment procurement completed.

  • Dhanuka Labs reported FY25 sales of INR 503 crores and an EBITDA of INR 42 crores, with its merger with Orchid Pharma expected to finalize in the next 6 months.

  • Management noted an unprecedented global slowdown in the antibiotics market, with oral antibiotics exports from India falling by about 30% and average export prices dropping by 15-20%.

Concerns

  • Persistent volume and price pressure in antibiotics market

Key financials

  1. Sales ₹173 Cr -29.1%YoY
  2. Gross Margin 42%
  3. Operational EBITDA ₹14 Cr

What they filed

Q1 FY27: revenue up 15.6%, net profit up 156.6% against the same quarter last year.

₹ Cr · quarterly
Line itemQ2 FY25Q3 FY25Q4 FY25Q1 FY26Q2 FY26Q3 FY26Q4 FY26Q1 FY27
Revenue223 217 237 263 194 −13%207 −5%368 +55%304 +16%
EBITDA30 26 28 -6 -1 −105%2 −94%30 +8%14 +348%
Net profit27 21 22 -6 -6 −121%-13 −161%26 +16%3 +157%
How to read this

₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.

Segment breakdown

  • Dhanuka Labs (FY25)
    ₹503 Cr Sales₹42 Cr EBITDA

Guidance & targets

Product Licensing

  • Exblifep out-licensing partner in U.S. Product Licensing · post acquisition completion · High confidence within 1 year
    Yes. Once the acquisition is completed, we will find an out-licensing partner in the U.S. and partner with them to launch, and we are targeting to do that within 1 year of acquisition completion.

    — Mridul Dhanuka, Whole-Time Director

Project Commissioning

  • 7ACA project commissioning Project Commissioning · Q1 FY27 · High confidence Q1 FY27
    Okay. Okay. And then on 7ACA commissioning is Q1 FY '27. Is that correct? Yes -- There is no change in what we mentioned last time. Yes.

    — Manish Dhanuka, Managing Director

  • Cefiderocol commissioning Project Commissioning · December '26 · High confidence December '26
    Okay. And Cefiderocol is December '26? Yes, yes.

    — Manish Dhanuka, Managing Director

Acquisition Completion

  • German IBC process (Allecra acquisition) Acquisition Completion · next 3 months · High confidence about 3 months
    We are expecting about 3 months.

    — Mridul Dhanuka, Whole-Time Director

Product Launch

  • Avibactam Orchid product availability Product Launch · early 2028 · High confidence 6 months after August 27
    The first to file launch date would be sometime in August 27, and Orchid product should be available 6 months after that.

    — Mridul Dhanuka, Whole-Time Director

Royalty Income

  • Significant royalty numbers from Exblifep Royalty Income · FY27 · Medium confidence next year
    It was launched just 6 months back. It takes time to develop the market. So in this year, we don't expect significant numbers coming out of royalty. We expect the growth will happen in next year.

    — Manish Dhanuka, Managing Director

Regulatory Filings

  • API DMF for Ceftaroline, Cefovecin Regulatory Filings · next 12 months · High confidence will be filed
    The DMF will be definitely filed.

    — Mridul Dhanuka, Whole-Time Director

Risks & concerns

  • Persistent volume and price pressure in antibiotics market

    high

    The antibiotics industry is facing an unprecedented global slowdown with both prices and volumes under pressure, leading to a 29% decline in Q1 FY26 sales.

    Management acknowledged

  • Uncertainty and limited due diligence regarding Allecra insolvency acquisition

    medium

    Insolvency acquisitions are conducted on an 'as is' basis with limited time for detailed due diligence, requiring further assessment post-completion.

    Management acknowledged

  • Global market turmoil and uncertainty leading to reduced customer inventories

    medium

    Management believes market uncertainty has led customers to reduce inventories, contributing to the sudden demand decrease, but expects recovery in 1-2 quarters.

    Management acknowledged

Areas of evasion (2)

  • Specific financial terms of Allecra acquisition
  • Revenue figures for Orblicef in India due to Cipla agreement

Q&A highlights

2 direct
Allecra acquisition details (cash outflow, royalty share, patent expiry) Partial
As per the terms of the agreement, it's confidential, especially right now because the CPs are also not completed. So we will only make the mandatory disclosures regarding the price in the reports as needed. ... So no debt will be taken to fund this acquisition. ... U.S., I can confirm its '24 -- early '24 -- '34, sorry. Yes. So other countries, Europe also is similar 2024 because the patents are filed similar time and exclusivity periods are also similar.

Analysts sought clarity on the financial implications (cost, funding, royalty structure) and patent protection for the newly acquired Enmetazobactam, which is a key growth driver.

Asked by Rupesh from Shree Rama Managers PMS

Enmetazobactam (Orblicef) sales in India vs. Avibactam, and U.S. out-licensing strategy Direct
See, first of all, this molecule should not be compared with Avibactam because that is a Pfizer molecule, and that is the last line, you can say, the reserve category of antibiotic, and that is used in extreme cases. Whereas this, we are trying to create a position where this can be used as a first line of antibiotic. ... The most prudent thing would be to close the deal within a year definitely because the NDA, the registration whole process has been completed.

This question probed the market positioning and sales potential of Orblicef in India, comparing it to a competitor, and sought timelines for the critical U.S. market entry strategy.

Asked by Rupesh from Shree Rama Managers PMS

Market conditions for antibiotics, especially penicillin prices and demand flattening Direct
Yes. So the penicillin prices have gone down significantly. So that's why I feel that there is a demand flattening because the raw material prices have also gone down. If the Chinese were also buying a lot of raw material, the raw material prices would still remain firm. ... That could be the only reason I can think of why sudden demand decrease is there. And I am optimistic that it should change in 1 or 2 quarters, and that would lead to a sudden recovery like what happened after the COVID.

Analysts were concerned about the broader market slowdown impacting revenues, and management's explanation provided insights into raw material price dynamics and inventory destocking as potential causes.

Asked by Viraj Parekh from Carnelian Asset Management

3 min read 6 chapters

Detailed narrative

Q1 FY26 Performance Amidst Global Antibiotics Slowdown

Orchid Pharma reported Q1 FY26 sales of INR 173 crores, marking a significant 29% year-over-year decline from INR 244 crores in the same period last year. This performance is attributed to an unprecedented global slowdown in the antibiotics market, characterized by both price and volume pressures. Despite these challenges, the company managed to maintain gross margins at approximately 42% through disciplined pricing and an optimized product mix. Operational EBITDA for the quarter stood at INR 14 crores, reflecting the difficult market environment.

Strategic Acquisition of Enmetazobactam Global Rights

A transformative development for Orchid Pharma is the acquisition of global rights to Enmetazobactam and the trademark Exblifep from Allecra. This acquisition grants Orchid complete control over the regulatory and commercial strategy for this novel antibiotic worldwide. Management highlighted that this makes Orchid the only Indian pharmaceutical company to innovate an internationally approved new chemical entity. While commercial terms remain confidential, the transaction is economically significant, with future double-digit royalties (estimated around 15%) from Advanz in Europe now accruing directly to Orchid.

Enmetazobactam (Orblicef) Market Strategy and Patent Outlook

Orchid Pharma plans to license out Enmetazobactam (Exblifep globally, Orblicef in India) to partners across the world, similar to Allecra's previous model. The product is already licensed in Europe, Middle East, and North African markets, with discussions ongoing for other geographies. The U.S. market remains a key focus, with a target to find an out-licensing partner within one year of acquisition completion. Patent expiry for Enmetazobactam is generally around early 2034 in the U.S. and similar in Europe, with ongoing pediatric studies potentially extending exclusivity.

Domestic Brand Performance and Antimicrobial Stewardship

Orblicef, Orchid's domestic brand in India, continues to perform steadily, leveraging Cipla's hospital coverage and Orchid's AMS division for prescriber awareness. The AMS division is expanding engagement with hospitals to promote responsible antibiotic use and AMR awareness, positioning Orchid as a trusted partner in critical care antibiotics. This platform is expected to drive the adoption of Cefiderocol in India, given its specialized prescriber base. The company aims to position Orblicef as a first-line antibiotic, targeting resistance to piperacillin-tazobactam and ceftriaxone.

Project Updates: 7ACA and Cefiderocol

The 7ACA project in Jammu is progressing as per revised timelines, with construction continuing and procurement of major engineering equipment completed. This facility is expected to strengthen API capabilities, reduce import dependencies, and deliver cost synergies. The commissioning of the 7ACA project is targeted for Q1 FY27. Additionally, the Cefiderocol project is on track, with commissioning expected by December '26.

Dhanuka Labs Merger and Market Outlook

The merger of Dhanuka Labs with Orchid Pharma is proceeding, with the results of the EGM accepted by the judge and final formalities expected to conclude within the next 6 months. Dhanuka Labs reported FY25 sales of INR 503 crores and an EBITDA of INR 42 crores. Management noted that the overall quantity of oral antibiotics exports from India fell by about 30% in Q1 FY26, with average export prices dropping by 15-20%. They are optimistic that the market will recover in 1-2 quarters, similar to post-COVID trends.

This is an AI-generated summary of a publicly available earnings call transcript.
View original transcript

More Healthcare earnings calls